Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00330200 · ClinicalTrials.gov registry record · Phase 2
Effects of ISIS 113715 on Insulin Sensitivity, Glucose, and Lipid Metabolism and Energy Expenditure in Type 2 Diabetics
A Phase 2 study, sponsored by Ionis Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT00330200 is a Phase 2 study that was terminated before completion, run by Ionis Pharmaceuticals. The registered enrollment target is 2 participants.
The verdict
NCT00330200, a Phase 2 study, was terminated before completion, sponsored by Ionis Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
The aim of this study is to examine the effects of ISIS 113715 monotherapy on insulin sensitivity, glucose and lipid metabolism and energy expenditure in subjects with type 2 diabetes mellitus.
Interventions
- DRUG ISIS 113715
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2005-11-01 |
| Est. Completion | 2007-03-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00330200
The ClinicalTrials.gov registry entry for NCT00330200 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ionis Pharmaceuticals, which has 76 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ISIS 113715 is the first listed.
NCT00330200 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00330200 about?
NCT00330200 is a clinical study titled "Effects of ISIS 113715 on Insulin Sensitivity, Glucose, and Lipid Metabolism and Energy Expenditure in Type 2 Diabetics". The aim of this study is to examine the effects of ISIS 113715 monotherapy on insulin sensitivity, glucose and lipid metabolism and energy expenditure in subjects with type 2 diabetes mellitus.
What is the current status of trial NCT00330200?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2005-11-01. Estimated completion is 2007-03-01.
What interventions are being tested in trial NCT00330200?
The interventions under investigation include: ISIS 113715 (DRUG).
Who is sponsoring clinical trial NCT00330200?
This trial is sponsored by Ionis Pharmaceuticals, which has 76 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.